https://www.selleckchem.com/pr....oducts/VX-680(MK-045
11, 95% CI - 0.35 to 0.12, I = 0%, p = 0.36). SGLT-2 inhibitor treatment did not have a significant impact either on SDNN (MD = - 2.83, 95% CI - 7.41 to 1.75, I = 31%, p = 0.23), or on r-MSSD (MD = - 0.14, 95% CI - 3.52 to 3.25, I = 46%, p = 0.94). Overall risk of bias was graded as low across the selected RCTs. SGLT-2 inhibitor treatment in patients with T2DM does not seem to provide any significant beneficial effect on CAN indices. SGLT-2 inhibitor treatment in patients with T2DM does not seem to provide any significant ben
Like
Comment
Share
